The changing epidemiology of GERD: Geography and Helicobacter pylori

American Journal of Gastroenterology

Volumn 98, Issue 7, 2003, Pages 1462-1470

  Graham, David Y ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS PH; GASTRITIS; GASTROESOPHAGEAL REFLUX; GEOGRAPHY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0037781591     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07533.x     Document Type: Review

References (80)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
2. Graham DY, Yamaoka Y. H. pylori and cagA: Relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998;3:145-51.
3. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
4. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998;12:735-40.
5. Stolte M, Bethke B. Elimination of Helicobacter pylori under treatment with omeprazole. Z Gastroenterol 1990;28:2714.
6. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994;121:161-7.
7. Meining A, Bosseckert H, Caspary WF, et al. H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997;11:729-34.
8. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-14.
9. Stolte M, Meining A, Schmitz JM, et al. Changes in Helicobacterpylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:247-53.
10. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
11. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46:615-21.
12. Berstad AE, Hatlebakk JG, Maartmann-Moe H, et al. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997;41:740-7.
13. Geboes K, Dekker W, Mulder CJ, et al. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: Clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001;15:1819-26.
14. Uemura N, Okamoto S, Yamamoto S, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000;14:1345-52.
15. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:135-670.
16. Kekki M, Saukkonen M, Sipponen P, et al. Dynamics of chronic gastritis in the remnant after partial gastrectomy for duodenal ulcer. Scand J Gastroenterol 1980;15:509-12.
17. Meikle DD, Taylor KB, Truelove SC, et al. Gastritis duodenitis, and circulating levels of gastrin in duodenal ulcer before and after vagotomy. Gut 1976;17:719-28.
18. Peetsalu A, Maaroos HI, Sipponen P, et al. Long-term effect of vagotomy on gastric mucosa and Helicobacter pylori in duodenal ulcer patients. Scand J Gastroenterol Suppl 1991;186:77-83.
19. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
20. Dore MP, Graham DY. Pathogenesis of duodenal ulcer disease: The rest of the story. Baillieres Best Pract Res Clin Gastroenterol 2000;14:97-107.
21. Olbe L, Fandriks L, Hamlet A, et al. Conceivable mechanisms by which Helicobacter pylori provokes duodenal ulcer disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14:1-12.
22. McColl KE, Dickson A, El Nujumi A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: Impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5.
23. Verdu EF, Fraser R, Armstrong D, et al. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994;29:1065-9.
24. Verdu EF, Armstrong D, Idstrom JP, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
25. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
26. Verdu EF, Armstrong D, Idstrom JP, et al. Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996;31:1151-6.
27. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725-32.
28. Labenz J, Tillenburg B, Peitz U, et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997;41:33-6.
29. Bercik P, Verdu EF, Armstrong D, et al. The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 2000;95:947-55.
30. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40.
31. Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12:1231-4.
32. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
33. Khoury RM, Katz PO, Hammod R, et al. Bedtime ranitidine does not eliminate the need for a second daily dose of ome prazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999;13:675-8.
34. Wilder-Smith C, Halter F, Ernst T, et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 1990;4(suppl 1):15-27.
35. Savarino V, Mela GS, Zentilin P, et al. Duration of acid suppression in H2-antagonist nonresponders. Digestion 1992;51:185-92.
36. Wilder-Smith CH, Merki HS. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol Suppl 1992;193:14-9.
37. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32.
38. Opekun AR, Smith JL, Graham DY. Antimony electrodes. Mucosal potential differences and buffer composition adversely affect pH measurements in the stomach. Dig Dis Sci 1990;35:950-5.
39. Opekun AR, Graham DY. Antimony electrodes for in vivo pH monitoring. Dig Dis Sci 1991;36:1180-1.
40. Kim HY, Kim YB, Park CK, et al. Co-existing gastric cancer and duodenal ulcer disease: Role of Helicobacter pylori infection. Helicobacter 1997;2:205-9.
41. Malaty HM, Kim JG, El-Zimaity HMT, Graham DY. High prevalence of duodenal ulcer and gastric cancer in dyspeptic patients in Korea. Scand J Gastroenterol 1997;32:751-4.
42. Graham DY. Therapeutic efficacy revisited. Dig Dis Sci 1984;29:589-90.
43. Blaser MJ. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease. J Infect Dis 1999;179:1523-30.
44. Boyd EJ. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996;91:1539-43.
45. Moraes-Filho JP, Zaterka S, Pinotti HW, et al. Esophagitis and duodenal ulcer. Digestion 1974;11:338-46.
46. Moraes-Filho JP. Lack of specificity of the acid perfusion test in duodenal ulcer patients. Am J Dig Dis 1974;19:785-90.
47. Flook D, Stoddard CJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. Br J Surg 1985;72:804-7.
48. Earlam RJ, Amerigo J, Kakavoulis T, et al. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. Gut 1985;26:95-100.
49. Goldman MS, Jr, Rasch JR, Wiltsie DS, et al. The incidence of esophagitis in peptic ulcer disease. Am J Dig Dis 1967;12:994-9.
50. Behar J, Biancani P, Sheahan DG. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. Gastroenterology 1976;71:9-15.
51. Winkelstein A. Peptic esophagitis with duodenal ulcer. Am J Surg 1957;93:234-7.
52. Casula G, Jordan PH, Jr. Is an antireflux procedure necessary in conjunction with parietal cell vagotomy in the absence of preoperative reflux? Am J Surg 1987;153:215-20.
53. Csendes A, Oster M, Moller JT, et al. Gastroesophageal reflux in duodenal ulcer patients before and after vagotomy. Ann Surg 1978;188:804-8.
54. Cruze K, Byron FX, Hill JT. The association of peptic ulcers and asymptomatic hiatal hernia. Surgery 1959;46:664-8.
55. Winkelstein A, Wolf BS, Som ML, et al. Peptic esophagitis with duodenal or gastric ulcer. JAMA 1954;154:885-9.
56. Benedict EB, Sweet RH. Benign stricture of the esophagus. Gastroenterology 1948;11:618-8.
57. Wallin L. Acid gastro-oesophageal reflux pattern in duodenal ulcer patients related to dyspeptic symptoms. Scand J Gastroenterol 1980;15:151-5.
58. Wallin L. The influence of cimetidine on the acid gastrooesophageal reflux in duodenal ulcer patients. Scand J Gastroenterol 1980;15:157-3.
59. Graham DY, Dixon MF. Acid secretion, Helicobacter pylori, and peptic ulcer disease. In: Graham DY, Genta RM, Dixon MF, eds. Gastritis. Philadelphia: Lippincott, Williams & Wilkins, 1999:177-88.
60. Vaezi MF, Richter JE. Duodenogastroesophageal reflux and methods to monitor nonacidic reflux. Am J Med 2001;111 (suppl 8A):160S-168S.
61. Challis RE, Fisher M, Hunt JN. Proceedings of the physiological society [proceedings]. J Physiol 1977;266:1P-2P.
62. Fisher MA, Hendrix TR, Hunt JN, et al. Relation between volume swallowed and velocity of the bolus ejected from the pharynx into the esophagus. Gastroenterology 1978;74:1238-40.
63. Mary DA, North PJ, Hunt JN. Scanning esophageal impedance probe for measurement of luminal cross section. Am J Physiol 1979;236:E545-E549.
64. Erol RA, Mangnall Y, Leathard AD, et al. Identifying oesophageal contents using electrical impedance tomography. Physiol Meas 1995;16:253-61.
65. Fass J, Silny J, Braun J, et al. Measuring esophageal motility with a new intraluminal impedance device. First clinical results in reflux patients. Scand J Gastroenterol 1994;29:693-702.
66. Rao SS, Ilayek B, Summers RW. Impedance planimetry: An integrated approach for assessing sensory, active, and passive biomechanical properties of the human esophagus. Am J Gastroenterol 1995;90:431-8.
67. Srinivasan R, Vela MF, Katz PO, et al. Esophageal function testing using multichannel intraluminal impedance. Am J Physiol Gastrointest Liver Physiol 2001;280:G457-G462.
68. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology 2001;120:1599-606.
69. Wenzl TG. Investigating esophageal reflux with the intraluminal impedance technique. J Pediatr Gastroenterol Nutr 2002;34:261-8.
70. Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664-8.
71. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
72. Levenstein H. Revolution at the table. The transformation of the American diet. London: Oxford University Press, 1988.
73. MacGregor GA, de Wardener HE. Salt, diet & health. Cambridge: Cambridge University Press, 1998.
74. Collins JH. The story of canned foods. New York: E.P. Dutton & Company, 1924.
75. Shephard S. Pickled, potted and canned. London: Headline Book Publishing, 2000.
76. Graham DY. Helicobacterpylori infection is the primary cause of gastric cancer. J Gastroenterol 2000;35(suppl 12):90-7.
77. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: A model. Gastroenterology 1997;113:1983-91.
78. Walsh GE. The expansion of winter farming. Sci Am 1902:252-3.
79. Prentice EP. Hunger and history: The influence of hunger on human history. New York: Harper & Brothers, 1939.
80. Taylor GR. The transportation revolution 1815-1860. New York: Harper & Row, 1951.